Trevena, Inc. Announces Poster Presentation Of Data For Delta Receptor Compound TRV250 At American Headache Society 57th Annual Scientific Meeting

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced that data highlighting its preclinical TRV250 program will be presented in a poster at the American Headache Society 57th Annual Scientific Meeting being held in Washington D.C., June 18 – 21, 2015.

Help employers find you! Check out all the jobs and post your resume.